Table 2.
Baseline clinical and laboratory characteristics of HCC patients.
| Factors | No. (%) | Median (range) |
|---|---|---|
|
| ||
| Age (years) | 445 | 60 (18-88) |
|
| ||
| Gender | ||
| Male | 395 (88.8) | |
| Female | 50 (11.2) | |
|
| ||
| ECOG performance status | ||
| 0 | 137 (30.8) | |
| 1 | 283 (63.6) | |
| 2 | 18 (4.0) | |
| 3 | 7 (1.6) | |
|
| ||
| Baseline biochemistry | ||
| Bilirubilin μmol/L, range) | 19 (3-548) | |
| Albumin (g/L) | 37 (8-53) | |
| ALT (iu/L) | 57 (12-564) | |
| Prothrombin time (s) | 12.3 (8.9-32.9) | |
| AFP (ng/mL) | 239 (1-3,637,000) | |
|
| ||
| Hepatitis B, % | 361 (81.1) | |
|
| ||
| Hepatitis C, % | 29 (6.5) | |
|
| ||
| Cirrhosis, % | 260 (58.4) | |
|
| ||
| Ascites | 111 (24.9) | |
|
| ||
| Vascular Involvement | 144 (32.4) | |
|
| ||
| Tumor number (Single : Multiple) | 165 : 280 | |
|
| ||
| Child-Pugh Class | ||
| A | 303 (68.1) | |
| B | 125 (28.1) | |
| C | 17 (3.8) | |
|
| ||
| AJCC stage | ||
| I | 17 (3.8) | |
| II | 112 (23.1) | |
| III | 57 (12.9) | |
| IV | 259 (58.2) | |
|
| ||
| Okuda stage | ||
| I | 203 (45.6) | |
| II | 202 (45.4) | |
| III | 40 (9.0) | |
|
| ||
| CUPI | ||
| Low risk | 224 (50.3) | |
| Medium risk | 164 (36.9) | |
| High risk | 57 (12.8) | |
|
| ||
| CUP score | ||
| 0 | 57 (12.8) | |
| 1 | 86 (19.3) | |
| 2 | 105 (23.6) | |
| 3 | 96 (21.6) | |
| 4 | 64 (14.4) | |
| 5 | 34 (7.6) | |
| 6 | 3 (0.7) | |
|
| ||
| BCLC stage | ||
| A | 64 (14.4) | |
| B | 107 (24.0) | |
| C | 251 (56.4) | |
| D | 23 (5.2) | |
|
| ||
| IL-8 (pg/mL) | 74.8 (2.0-1670.5) | |
|
| ||
| Log IL-8 | 1.87 (0.31-3.22) | |
| <1.8 | 207 (46.5) | |
| ≥1.8 | 238 (53.5) | |
|
| ||
| Modified inflammation-based index | ||
| 0 | 109 (24.5) | |
| 1 | 127 (28.5) | |
| 2 | 123 (27.6) | |
| 3 | 86 (19.3) | |
|
| ||
| C-reactive protein (mg/L) | 11.13 (0.05-17.62) | |
| ≤10 | 199 (44.7) | |
| >10 | 246 (55.3) | |
|
| ||
| First-line treatment | ||
| surgical intervention | 51 (11.5) | |
| Percutaneous RFA/ethanol injection | 28 (6.3) | |
| LEM/TACE/TAE | 110 (24.7) | |
| systemic therapy | 85 (19.1) | |
| Best supportive care | 171 (38.4) | |
Abbreviations: AFP, α-fetoprotein; AJCC, American Joint Committee on Cancer; ALT, alanine transaminase; BCLC, Barcelona clinic liver cancer; CLIP, the Cancer of the Liver Italian Program; CUPI, the Chinese University Prognostic Index; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; LEM, transarterial lipiodol-ethanol mixture; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TAE, transarterial embolization.